Multinational Pharma Patent-Cliff Anxiety

Multinational pharma patent-cliff anxiety is the episode’s explanation for why large drug companies can become aggressive buyers of external assets. In vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位, the clearest case is 默沙东 and K药: a blockbuster product creates today’s revenue strength and tomorrow’s replacement pressure when exclusivity weakens.

The source uses patent-cliff anxiety to interpret MNC behavior around Chinese assets. A company can publicly demand better survival data or mechanism proof, while still buying options if an external asset could defend a core franchise or fill a future revenue hole.

156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 broadens the concept from Merck alone to the 2025 BD boom. The episode uses 默沙东’s Keytruda and HPV-vaccine pressure as examples of why MNCs need new pipelines, while Chinese companies offer lower-cost, increasingly credible assets.

Key Claims

• A large current product can become a strategic vulnerability when patent expiration approaches.
• Patent-cliff risk makes external BD, M&A, and China pipeline buying more urgent.
• PD-1/VEGF Bispecific is important in the source partly because it can threaten or extend a PD-1 franchise logic.
• The concept explains corporate behavior, not the clinical truth of any single molecule.
• Episode 156 adds that patent-cliff anxiety helps explain record China BD, but clinical and commercial validation still come later.

Connections

• Merck / 默沙东, Keytruda / K药, and Bristol Myers Squibb / BMS - PD-1 and patent-cliff examples.
• Akeso / 康方生物, China Biotech Asset Repricing, and Biotech License-Out Arbitrage - China asset-buying branch.
• Gilead Sciences / 吉利德 - company contrast where antiviral success and oncology setbacks coexist.
• Investment Risk Management - boundary around turning corporate anxiety into investment conclusions.
• Biotech BD Data Validation Phase, Clinical Data Trust Rebuilding, and Platform-Level Biotech BD - episode 156 demand and validation context.